Information about merck medco prescription discount drug card





 

Share on Facebook Share on Twitter Email

On this page
Library

Animal Life
Business & Finance

Entertainment & Arts
Food & Cooking

Health
History, Politics, Society

Home & Garden
Law & Legal Issues

Literature & Language
Miscellaneous

Religion & Spirituality
Science

Shopping
Sports

Technology
Travel

Q & A
Answers.com

Medco Containment Services Inc
==============================
Company History:

Medco Containment Services Inc
------------------------------
Home > Library > Business & Finance > Company Histories

Type: Public Company
Address: 100 Summit Avenue, Montvale, New Jersey 07645, U.S.A.
Telephone: (201) 358-5400
Fax: (201) 358-5783
Employees: 9,400
Sales: $2.6 billion
Incorporated: 1983
SIC: 5122 Drugs, Proprietaries & Sundries; 5961 Catalog & Mail-Order
Houses
Medco Containment Services Inc. controls more than 50 percent of one
of the fastest growing segments of the health-care industry, the
funded mail-order prescription drug trade in the United States. Within
ten years of its founding in 1983, it was serving 36 million workers
from more than 3,100 client companies. In addition, it was dispensing
more than 600,000 prescriptions weekly from its eleven regional
distribution centers. Health care and financial experts anticipated
that health care reform policies would further enhance Medco's
business.

Martin Wygod spent his first 20 years after college in small-scale
investment banking and acquisitions, in addition to owning a
controlling interest in Porex Technologies Corp. In 1983, with $10
million from the sale of one of his investments, he went shopping for
a new challenge. Wygod formed Medco as a holding company so he could
buy National Pharmacies for $30 million in cash and Porex stocks.
National Pharmacies, owned by APL Corporation, was a vitamin
distributor and a small mail-order prescription drug business. It had
yearly revenues of about $25 million and profits of about $400,000.
Wygod eliminated the vitamin business and built up the mail-order drug
business.
Although the Veterans Administration and other nonprofit groups had
handled long-term prescriptions by mail for almost 40 years, in 1984
mail-order drugs accounted for only two percent of the prescriptions
filled in the United States. But Wygod's timing was perfect. Large
corporations were looking for ways to save money on employee drug
costs, and mail order was a convenient way to save on long-term
prescriptions for the chronically ill patient. Wygod aggressively
sought new clients for his mail-order company and quickly signed up
corporate-funded drug benefit plans offered by Alcoa, General Motors,
Georgia-Pacific, and Commonwealth Edison Co. By 1992, Medco had more
than 1,300 company accounts. Medco grew from 200 employees serving
fewer than four million people in 1985 to 6,000 employees serving
close to 30 million people in 1993. Within ten years, Medco controlled
50 percent of the prescription mail business nationally, and its
revenues were consistently growing by an average of 47 percent a year.

Although Medco was not the first mail-order prescription company, it
was the first company that aggressively sold its services to large
corporations, labor unions, and health plans. When Wygod bought
National Pharmacies, the cost of employee drugs as an employment
benefit was rising 15 percent to 20 percent a year, and only five
percent of employees were covered by drug plans. By 1991, more than 40
percent were covered.
In 1984, Wygod sought underwriting by Drexel Burnham and sold 20
percent of the company in a public offering. That same year, the
company's name was changed to Medco Containment Services Inc. In 1985,
Wygod acquired Paid Prescriptions from Computer Sciences Corp. This
small company provided plan subscribers with a prescription-drug card
that allowed them to purchase drugs at 40,000 drugstores, who then
billed the plan sponsors. This acquisition allowed Medco to offer plan
participants the ability to fill prescriptions for acute illness at a
discount at participating drugstores. While mail-order prescriptions
of preferred drugs cost a minimal co-payment of $2, participants could
also purchase drugs at a local store for a higher co-payment. This
computer network also allowed Medco to gather information on consumer
prescription drug spending and sell that information to the nation's
largest health plan sponsors.

Walgreen Co. had dominated the mail-order prescription business when
Wygod bought National Pharmacies. But Wygod anticipated that Walgreen
would not expand that operation because if it did it would be
competing against its own local drugstores. Wygod's Medco surged ahead
of Walgreen in mail-order operations. It has since taken market share
from mail-order drug companies owned by Baxter International and J.C.
Penney, as well as retail drugstore chains such as Walgreen and
Rite-Aid. Independent retail pharmacists and state pharmacy boards
have lobbied to restrict mail-order sales and have even brought legal
suits protesting the sending of drugs across state lines, but they
have had no success in stopping Medco or other mail-order prescription
services.
Medco specialized in maintenance drugs for high blood pressure,
arthritis, diabetes, and other chronic diseases. Patients still
shopped at local pharmacies for antibiotics and other prescriptions
needed for acute illnesses, but chronic ailments which called for
regular drug therapy were increasingly being serviced by Medco and
smaller mail-order companies. Medco claimed to save at least 20
percent on most prescriptions because it encouraged the use of generic
drugs and it could negotiate healthy discounts from manufacturers. In
the early 1990s, providing prescription drug coverage cost employers
in a Medco-run plan about $167 per employee versus $266 per employee
in unmanaged plans.

In late 1990, Medco introduced a controversial program called
Prescriber's Choice: for a deep discount from a drug company, Medco
would promote that company's drug as the top choice in its category.
The Prescriber's Choice program covered many chronic conditions such
as hypertension and ulcers, for which there were drugs priced at
various levels. When the company believed a physician had ordered a
more expensive drug than necessary, a pharmacist reviewed the
patient's questionnaire that revealed his/her ailments and other
medications. Then the pharmacist contacted the physician and told her
about another equally effective but less costly alternative. The
physician was free to change the prescription to the less expensive
treatment or chose the drug they had originally prescribed. However,
statistics showed that more than 40 percent of physicians agreed to
rewrite their prescriptions. According to the Wall Street Journal,
Medco was switching--with doctors' permission--50,000 prescriptions
monthly in eight major drug categories. Once Medco had called doctors'
attention to the cheaper drug, they often started prescribing that
drug for other patients as well.
Ulcers was one of the first categories that Medco addressed with its
Prescriber's Choice program. This was an excellent category to choose
since patients were repeat customers for refills, sales of ulcer
medication were vast, and there were only four similar drugs doctors
generally prescribed. Medco negotiated with the makers of the four
drugs, Glaxo, SmithKline Beecham, Merck, and Eli Lilly & Co. In the
summer of 1991, SmithKline Beecham's Tagamet became Medco's number one
choice for ulcer prescriptions. Patients could get any of the other
medications, but Tagamet was the most cost-effective because of the
volume discount Medco won in exchange for listing that drug as its top
choice. Medco accounted for ten percent of the ulcer medication's
$3-billion-a-year market. Health plans paid a lower cost for Tagemet
and patients paid a lower co-payment for Tagamet than they would for
the other medications.

Medco also established a formulary for 18 other categories of
medication. Under this plan, Medco listed a small number of
medications in each category; Medco would reimburse most of patients'
costs if they were using drugs from the Medco listing. Patients,
however, had to pay a higher amount for drugs not listed in the
formulary. In a formulary Medco established in Massachusetts, the
co-payment was $8 for a generic drug, $15 for a brand in the
formulary, and $30 for a brand outside the formulary. Medco often
ended up recommending older drugs with small market share because the
smaller companies tended to cut prices in order to increase their
market share.
Although many doctors, retail pharmacists, and drug companies
complained about formularies and Medco's Prescriber's Choice, it
seemed to be the direction prescription drug distribution would take
as managed care gained momentum in the United States. According to
Wygod, the Prescriber's Choice program offered cost containment and
choice while other formularies offered no choice. In formularies,
patients may be reimbursed for only one or two of the drugs prescribed
for a particular ailment and all other drugs are excluded. Some
experts predicted, however, that by the year 2000, prescription
purchases would be decided by committees rather than by individual
prescribing physicians. These large buying groups would reduce drug
costs since buyers would have volume-purchasing power. Formularies
were seen as a means of controlling prescription drug costs by
changing physicians' prescribing habits. Formularies listed
nonformulary drugs and the recommended cheaper alternatives.

Physicians, pharmacists, and some drug companies pointed out that
prescription choices should be made on a therapeutic basis rather than
a cost basis, but Medco and other health plans and organizations
seemed determined to keep the formularies. Drug companies, especially
when their products were not adopted on formularies, argued that cost
comparison should not be the only criteria on which to base a choice.
They argued that the physician and the health agency needed to look at
the overall picture and that some drugs could prevent the need for
surgery. They also pointed out that although some drugs might have a
higher per-dose cost, the total course of therapy might cost less
because fewer doses were needed.
Retail pharmacists complained that they could not get the same price
breaks that giant Medco won from manufacturers. Some physicians
complained that Medco and other formularies were taking control away
from the physician. And some drug companies complained that Medco
exercised too much control over the drug market because it had the
power to promote one drug over another to the tens of millions of
patients it served. Because Medco controlled such a large share of the
prescription market, Medco's deals could heavily influence sales of
many drug categories and shift the balance from one drug to another.
Many drug makers were unhappy about this, but they could not afford to
alienate Medco. By 1993, all but a handful of major U.S.
pharmaceutical firms had signed on with Medco.

Medco chairman Martin Wygod was one of the five highest-paid CEOs in
the United States in 1992, earning a $33-million pay package, much of
it in stock options. Wygod told the Wall Street Journal that he
deserved that immense compensation for making the company "the
Wal-Mart of pills." Medco was able to offer medications for 25 percent
less than retail pharmacies because of volume discounts and automation
that helped each pharmacist or technician process 70 prescriptions an
hour, even with each order reviewed for accuracy by two pharmacists.
In 1992, former Citibank President Richard Braddock became CEO of
Medco--later resigning in September of 1993--while Wygod retained his
position as chairman of the company. The top jobs were split so that
Wygod could concentrate on acquisitions and dealings with drug
companies while Braddock focussed on operations. Wygod said that
Braddock's skills were important for helping the company through a
"major growth stage." Braddock also noted that health-care reform
could benefit Medco and other companies that stress cost containment.

Medco's growth has been steady and dramatic since its inception in
1984. For five years in a row, Medco's revenues increased an average
of 47 percent annually, and its earnings gained an average of 45
percent a year. In 1991, Medco's revenue increased only 35 percent, to
$1.81 billion, but its net income leaped 75 percent, to $102 million.
In 1992, revenue was above $2 billion. By 1993, more than 100 of the
Fortune 500 companies had signed on with Medco.
In 1991, Comnet Corporation, a producer of direct-marketing and
health-care software, sold Medco enough stocks to give Medco a 23
percent share. Wygod also became chairman of Comnet as well as Medco.
That same year, Medco launched Medical Marketing Group Inc. to collect
data from drugstores and physicians on prescribing patterns and sell
the data to drug companies for their promotional or marketing needs.
Medical Marketing gathered the information chiefly from IMS America
Ltd., a Dun & Bradstreet division that collects data from pharmacies.
The balance of Medical Marketing's data came from Medco and the
mail-order prescription service of the American Association of Retired
Persons (AARP).

In 1991, Medco completed a deal to acquire American Biodyne Inc., a
provider of managed mental health services. Medco paid $121 million in
Medco common stock. Medco also acquired Personal Performance
Consultants, which provided employee assistance programs. In 1991,
Medco also established the Medco Foundation and the Rose Foundation to
provide prescription drug aid for uninsured and impoverished people.
Health-care related companies were anxiously waiting as American
politicians hammered out health-care reform measures in 1993. Medco,
however, seemed to be in a good position to benefit from any
managed-care program, a likely component of any reform measure.
Companies such as Medco, which can provide drugs on a large scale and
at a lower price than other outlets, were poised to take advantage of
the health care reform legislation and employer and health plan
efforts to contain costs.

According to Forbes, in 1990, about $10 billion in maintenance drugs
were funded by drug benefit plans other than Medicaid, with only $2
billion provided through mail-order services. By 1995, maintenance
drug costs would almost triple, according to Forbes, and the
mail-order share would be about $7 billion. Some drug companies were
predicting that by 1995, 60 to 65 percent of all outpatient drugs
would by funded. With Medco's 50 percent or higher mail-order market
share, it was looking forward to healthy growth for the rest of the
decade. Wygod told the Washington Post that his goal was to provide
"each patient with the right medication at the right time for the
right reason--at a price that is affordable to the plan sponsor."
Principal Subsidiaries

Medical Marketing Group; Synetic Inc.; Medco Behavioral Care Corp.
Further Reading

Anders, George, "Medicine: Pharmacy Chain's Successful Sales Pitch
Dismays Some Doctors and Drug Firms," Wall Street Journal, February
26, 1993, p. B1.
Mathews, Jay, "Medco's 'Managed Care' Hits the Pharmacy Business,"
Washington Post, February 28, 1993, p. H1.

O'Reilly, Brian, "Rx for Costs: Drugs by Mail," Fortune, August 24,
1992, p. 116.
Peers, Alexandra and Michael Siconolfi, "Inside Track: Medco Officials
Take Profits from Big Gains," Wall Street Journal, January 29, 1992,
p. C1.

Rudnitsky, Howard, "Drugs by Mail," Forbes, April 15, 1993, pp. 60-61.
Winslow, Ron, "Buyer's Market: Prescribing Decisions Increasingly Are
Made by the Cost Conscious," Wall Street Journal, September 25, 1992,
p. A1.

— Wendy J. Stein
Home of Wiki & Reference Answers, the world’s leading Q&A siteReference AnswersEnglish▼English▼
Deutsch Español Français Italiano Tagalog 

 
 

Search unanswered questions...
Browse: Unanswered questions  Most-recent questions  Reference
 library

Enter a question here...Search: All sources Community Q&A Reference
topics
Browse: Unanswered questions  New questions  New answers 
 Reference library

Related Videos:
Medco Containment Services Inc
------------------------------

Top Learn More
 

Merck & Co., Inc.
 

Medco Health Solutions
 

Is it inc or inc? Read answer...
 

Who is agent for service of process for jb hunt transport services inc.?
Read answer...
 

What is and inc? Read answer...
Help us answer these

 
What is CUSO Financial Services Inc?

 
Does Medco pay for shingles vaccine?

 
About Select Portfolio Servicing Inc?

Post a question - any question - to the WikiAnswers community:
Copyrights:

Company History. International Directory of Company Histories.
Copyright © 2006 by The Gale Group, Inc. All rights reserved. Read
more
Related answers

Engineering and Manufacturing Services Inc?
What is the Christian Information Service Inc?

What is OSI collection services inc?
What is Inc?

» More ADVERTISEMENT Answer these
Is medco containment services aware of precisionrx.com and
 nextrx.com?

At and t services inc?
Who is Classic Services Inc?

» More
Mentioned in

Merck & Co., Inc.
Medco Health Solutions

Site
Help

Sitemap
ReferenceAnswers

WikiAnswers
Company

About  Jobs
Press Room

Blog  Facebook Twitter YouTube
Investor Relations

Legal
Terms of Use

Privacy Policy
IP Issues

Disclaimer
Webmasters

AnswerTips
Widget Gallery

Badges
More…

Downloads
1-Click Answers

Browser Toolbar
More…

Updates
Email

Watchlist
RSS

What's New
International Sites English Deutsch Español Français Italiano Tagalog

Copyright © 2010 Answers CorporationQuantcast
above she where she she both my over below yourself through the myself nor merck medco prescription discount drug card
surely or under me each between was again
during be! look through and
such ours herself between or by until myself
go there! hello does ours on he out all through he no both itself be! most
an while am does whom
she in those from your do you maybe we him
discount prescription drugs the no visit - a for after them Right on!
maybe been theirs if these their about same been being myself am himself our some
merck medco prescription discount drug card on discount prescription drugs there through then for here having once are she nor
very am discount prescription drugs did if those i Right on! hello during do does see few that outta sight
through Right on! outta sight are can but any is
being them your there so off its should be is once your
from Like, theirs over out was once where until in her in
a too if are from than this
which where and have if against having being